Phase IIB trial of the immunological mechanism of PV 10, an injectable formulation of rose bengal sodium, in patients with malignant melanoma

Trial Profile

Phase IIB trial of the immunological mechanism of PV 10, an injectable formulation of rose bengal sodium, in patients with malignant melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2013

At a glance

  • Drugs Rose bengal sodium (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 10 Apr 2013 Status changed to discontinued, according to information provided by Provectus Pharmaceuticals.
    • 09 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top